Skip to main content
Premium Trial:

Request an Annual Quote

Solgent Coronavirus Test Gets CE Mark, EUA from Korean, Philippines Authorities

NEW YORK – SolGent said on Thursday that it has received the CE mark for its DiaPlexQ Novel Coronavirus (2019-nCoV) Detection assay, as well as authorization from regulatory authorities in Korea and the Philippines.

The company's test qualitatively detects the Orf1a and N genes of the novel coronavirus in sputum, oropharyngeal, and nasopharyngeal specimens from patients with suspected respiratory infection.

SolGent, based in South Korea, received the CE mark on Feb. 26, emergency use authorization from the Korean Ministry of Food and Drug Safety on Feb. 27, and approval from the Philippines Department of Health Food and Drug Administration on March 19.

Solgent is a subsidiary of Eone-Diagnomics Genome Center (EDGC), which is based in Incheon, a city near Seoul.



The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.